API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AARTI DRUGS LTD

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER  2011
(` In Lacs except for share data)
PARTICULARS Quarter Ended Quarter Ended Half Year Ended Half Year Ended Year ended
30th Sept 11 30th Sept 10 30th Sept  2011 30th Sept  2010 31st Mar 2011
1.Gross Sales / Income from operations 15,348 11,444 31,037 23,659 52,301
Less : Excise Duty & Sales Tax 898 605 1,779 1,315 2,659
(a) Net Sales / Income from operations 14,450 10,839 29,258 22,344 49,642
(b) Other Operating Income - - - - -
2. Expenditure
(a). (Increase) / Decrease in stock in trade & WIP (1,412) (838) (2,224) (1,264) (1,618)
(b). Consumption of raw materials. 9,141 6,387 18,495 12,355 27,300
(c). Purchase of Traded Goods 2,113 1,721 3,893 3,951 8,421
(d). Employees cost 487 401 992 805 1,646
(e).  Depreciation 448 377 883 738 1,548
(f). Other expenditure 2,584 1,739 5,071 3,547 7,858
(g). Total Expenditure 13,361 9,787 27,110 20,132 45,155
3. Profit from Operations before Other Income, 1,089 1,051 2,148 2,212 4,487
Interest & Exceptional Item
4. Other Income 2 4 6 5 8
5. Profit before Interest & Exceptional Items 1,091 1,055 2,154 2,217 4,495
6. Interest 440 288 840 562 1,348
7. Profit after Interest but before Exceptional Items 651 767 1,314 1,655 3,147
8. Exceptional Items - - - - -
9. Profit from Ordinary Activities before Tax 651 767 1,314 1,655 3,147
10. Tax Expenses (Includes) 159 249 360 540 900
Provision for Taxation 119 179 282 402 650
Provision for Deffered Taxation 40 70 78 138 250
11. Net profit from ordinary Activities after Tax 493 518 954 1,116 2,247
12. Extraordinay Item (net of tax expenses ) - - - - -
13. Net Profit for the period 493 518 954 1,116 2,247
14. Paid-up Equity Share Capital of Rs.10/- each. 1,211 1,211 1,211 1,211 1,211
15. Reserves & Surplus (excluding revaluation reserves) - - - - 14,441
16. Basic  E P S(in Rs.) 4.07 4.28 7.88 9.21 18.56
17. Public shareholding
-Number of Shares 5493177 5827828 5493177 5827828 5569613
-Percentage of Total Shareholding 45.37 48.13 45.37 48.13 46.00
18.Promoters & Promoter Group
Shareholding
a) Pledged/Encumbered
- Number of Shares NIL NIL NIL NIL NIL
-Percentage of shares( as a percentage of the NIL NIL NIL NIL NIL
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of NIL NIL NIL NIL NIL
total sharecapital of the Company)
b) Non-encumbered
- Number of Shares 6615373 6280722 6615373 6280722 6538937
-Percentage of shares( as a percentage of 100 100 100 100 100
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of 54.63 51.87 54.63 51.87 54.00
total sharecapital of the Company)
Notes :
1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held  on 11th November, 201
2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement  as per AS - 17 'Segment Reporting' is not attracted.
3. The figures of the previous periods have been regrouped and rearranged wherever necessary.
4. Number of Investors complaints (i) pending at the begining of quarter 0 (ii) received during the quarter : 4 (Iii) redressed :2 (iv) pending at the end of the quarter  : 2.
5. Statement of Assets and Liabiliites as on 30.09.2011 is annexed .
For and on behalf of the Board
For AARTI DRUGS LIMITED
Sd/-
Place : Mumbai Harshit M Savla
Date : 11 November, 2011 (Jt. Managing Director)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech